関連レポート

変形性関節症治療薬の世界市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年4月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 205ページになります。

商品コード：TMR256

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

リウマチ治療薬の世界市場規模は2023年で488億ドル、2034年に651億ドル、市場の平均年成長率は2.3%になる見込みです。

当レポートでは、リウマチ治療薬の市場予測-2034年、各種セグメント別市場分析(薬剤クラス別、適応障害別、国地域別、等)、市場シェア分析、SWOT分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■リウマチ治療薬の世界市場予測2020-2034年
・市場規模(US$)

■薬剤クラス別、市場-2034年
疾患修飾性抗リウマチ薬（DMARDs）
・合成疾患修飾性抗リウマチ薬
・生物学的疾患修飾性抗リウマチ薬

非ステロイド性抗炎症薬（NSAIDs）
副腎皮質ステロイド薬
尿酸薬
その他
※(市場規模US$)

■適応疾患別、市場-2034年
関節リウマチ
・変形性関節症
・痛風
乾癬性関節炎
強直性脊椎炎
その他
※(市場規模US$)　

■投与経路別、市場-2034年
非経口
経口
局所
※(市場規模US$)　

■流通経路別、市場-2034年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析
SWOT分析

■リウマチ治療薬の主要企業プロフィール動向
Merck & Co., Inc.
AbbVie, Inc.
Bristol-Myers Squibb Company
Pfizer, Inc.
武田薬品工業株式会社
Amgen, Inc.
Genentech, Inc.
Novartis AG
Johnson & Johnson Innovative Medicine
F. Hoffmann-La Roche AG
Sanofi
（全205頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Rheumatology Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.3.3. Corticosteroids
6.3.4. Uric Acid Drugs
6.3.5. Others
6.4. Market Attractiveness, by Drug Class

7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Rheumatoid Arthritis
7.3.2. Osteoarthritis
7.3.3. Gout
7.3.4. Psoriatic Arthritis
7.3.5. Ankylosing Spondylitis
7.3.6. Others
7.4. Market Attractiveness, by Disease Indication

8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Parenteral Route
8.3.2. Oral Route
8.3.3. Topical
8.4. Market Attractiveness, by Route of Administration

9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness, by Distribution Channel

10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Rheumatology Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2020-2034
11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.2.3. Corticosteroids
11.2.4. Uric Acid Drugs
11.2.5. Others
11.3. Market Attractiveness, by Drug Class
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Rheumatoid Arthritis
11.4.2. Osteoarthritis
11.4.3. Gout
11.4.4. Psoriatic Arthritis
11.4.5. Ankylosing Spondylitis
11.4.6. Others
11.5. Market Attractiveness, by Disease Indication
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Parenteral Route
11.6.2. Oral Route
11.6.3. Topical
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Class
11.11.2. By Disease Indication
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country

12. Europe Rheumatology Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
12.2.3. Corticosteroids
12.2.4. Uric Acid Drugs
12.2.5. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Rheumatoid Arthritis
12.4.2. Osteoarthritis
12.4.3. Gout
12.4.4. Psoriatic Arthritis
12.4.5. Ankylosing Spondylitis
12.4.6. Others
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Parenteral Route
12.6.2. Oral Route
12.6.3. Topical
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Pharmacy
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Class
12.11.2. By Disease Indication
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region

13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
13.2.3. Corticosteroids
13.2.4. Uric Acid Drugs
13.2.5. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Rheumatoid Arthritis
13.4.2. Osteoarthritis
13.4.3. Gout
13.4.4. Psoriatic Arthritis
13.4.5. Ankylosing Spondylitis
13.4.6. Others
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Parenteral Route
13.6.2. Oral Route
13.6.3. Topical
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Class
13.11.2. By Disease Indication
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region

14. Latin America Rheumatology Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
14.2.3. Corticosteroids
14.2.4. Uric Acid Drugs
14.2.5. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Rheumatoid Arthritis
14.4.2. Osteoarthritis
14.4.3. Gout
14.4.4. Psoriatic Arthritis
14.4.5. Ankylosing Spondylitis
14.4.6. Others
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Parenteral Route
14.6.2. Oral Route
14.6.3. Topical
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Pharmacy
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Class
14.11.2. By Disease Indication
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region

15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
15.2.3. Corticosteroids
15.2.4. Uric Acid Drugs
15.2.5. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Rheumatoid Arthritis
15.4.2. Osteoarthritis
15.4.3. Gout
15.4.4. Psoriatic Arthritis
15.4.5. Ankylosing Spondylitis
15.4.6. Others
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Parenteral Route
15.6.2. Oral Route
15.6.3. Topical
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. Online Pharmacy
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Class
15.11.2. By Disease Indication
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. AbbVie, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Takeda Pharmaceutical Company Limited
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Amgen, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Genentech, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Johnson & Johnson Innovative Medicine
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sanofi
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Merck & Co., Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034

Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 06: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034

Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 11: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 12: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034

Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 16: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 18: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034

Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 21: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 23: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 24: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034

Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

Table 26: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 27: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034

Table 28: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 29: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034

Table 30: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034

Figure 02: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Drug Class, 2023

Figure 03: Global Rheumatology Therapeutics Market Value Share, by Drug Class, 2023

Figure 04: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Disease Indication, 2023

Figure 05: Global Rheumatology Therapeutics Market Value Share, by Disease Indication, 2023

Figure 06: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023

Figure 07: Global Rheumatology Therapeutics Market Value Share, by Route of Administration, 2023

Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023

Figure 09: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023

Figure 10: Global Rheumatology Therapeutics Market Value Share, by Region, 2023

Figure 11: Global Rheumatology Therapeutics Market Value (US$ Mn) Forecast, 2020-2034

Figure 12: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 15: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 16: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 17: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023

Figure 19: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023

Figure 20: Global Rheumatology Therapeutics Market Value Share Analysis, by Region, 2023 and 2034

Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region, 2024-2034

Figure 22: North America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 23: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country, 2024-2034

Figure 24: North America Rheumatology Therapeutics Market Value Share Analysis, by Country, 2023 and 2034

Figure 25: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 26: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 27: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 28: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 29: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 30: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 31: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 32: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 33: Europe Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 34: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 35: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 36: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 37: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 38: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 39: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 40: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 41: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 42: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 43: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 44: Asia Pacific Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 45: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 46: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 47: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 48: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 49: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 50: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 51: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 52: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 53: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 54: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2034

Figure 55: Latin America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 56: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 57: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 58: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 59: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 60: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 61: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 62: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 63: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 64: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 65: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 66: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 67: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 68: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 69: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 70: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 71: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 72: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 73: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034

Figure 74: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 75: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 76: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034

△ 一番上に戻る